Lipoprotein (a) measurements for clinical application
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific antibodies directed to apo(a) more difficult and poses significant challenges to the development of immunoassays to measure its concentration in plasma or serum samples. Apo(a) is extremely variable in size not only between but also within individuals because of the presence of two different, genetically determined apo(a) isoform sizes. Therefore, the antigenic determinants per particle available to interact with the antibodies will vary in the samples and the calibrators, thus contributing to apo(a) size-dependent inaccuracy of different methods. The lack of rigorous validation of the immunoassays and common means of expressing Lp(a) concentrations hinder the harmonization of results obtained by different studies and contribute to the lack of common cut points for identification of individuals at risk for coronary artery disease or for interventions aimed at reducing Lp(a) levels. The aim of our review is to present and critically evaluate the issues surrounding the measurements of Lp(a), their impact on the clinical interpretation of the data, and the obstacles we need to overcome to achieve the standardization of Lp(a) measurements.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note that direct LDL-C measurements also have limitations, including systematic bias and inaccuracy in patients with dyslipidaemia, especially for high TG levels [88-90].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [90]
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558
A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction
Ridker, P. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180065035 · Cited by 512
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Self-citationSandholzer, C., Hallman, D. M., Saha, N., Sigurdsson, G., Lackner, C., Cs�sz�r, A., Boerwinkle, E., & Utermann, G. (1991) · Human Genetics · doi:10.1007/bf00201550 · Cited by 386
Marcovina, S. M., Albers, J. J., Gabel, B., Koschinsky, M. L., & Gaur, V. P. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.2.246 · Cited by 354
Self-citationVirani, S. S., Brautbar, A., Davis, B. C., Nambi, V., Hoogeveen, R. C., Sharrett, A. R., Coresh, J., Mosley, T. H., Morrisett, J. D., Catellier, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.045120 · Cited by 324
Molecular definition of the extreme size polymorphism in apolipoprotein(a)
Lackner, C., Cohen, J. C., & Hobbs, H. H. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.933 · Cited by 319
Marcovina, S. M., Albers, J. J., Scanu, A. M., Kennedy, H., Giaculli, F., Berg, K., Couderc, R., Dati, F., Rifai, N., Sakurabayashi, I., et al. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.1956 · Cited by 313
Self-citationEffects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)
Maher, V. M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220037029 · Cited by 298
Marcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Self-citationRadioimmunoassay of human plasma Lp(a) lipoprotein
Albers, J. J., Adolphson, J. L., & Hazzard, W. R. (1977) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41683-9 · Cited by 268
Self-citationDifferences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans
Marcovina, S. M., Albers, J. J., Wijsman, E., Zhang, Z., Chapman, N. H., & Kennedy, H. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37461-7 · Cited by 237
Self-citationMarcovina, S. M., Zhang, Z. H., Gaur, V. P., & Albers, J. J. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1343 · Cited by 225
Self-citationImmunochemical quantification of human plasma Lp(a) lipoprotein
Albers, J. J., & Hazzard, W. R. (1974) · Lipids · doi:10.1007/bf02533209 · Cited by 217
Self-citationLipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O'Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., Domanski, M., Arai, K., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.042 · Cited by 215
Guan, W., Cao, J., Steffen, B. T., Post, W. S., Stein, J. H., Tattersall, M. C., Kaufman, J. D., McConnell, J. P., Hoefner, D. M., Warnick, R., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304785 · Cited by 215
Koschinsky, M. L., Côté, G. P., Gabel, B., & van der Hoek, Y. Y. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36587-1 · Cited by 214
Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies
Craig, W. Y., Neveux, L. M., Palomaki, G. E., Cleveland, M. M., & Haddow, J. E. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.11.2301 · Cited by 210
von Eckardstein, A., Schulte, H., Cullen, P., & Assmann, G. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01126-8 · Cited by 187
Hoek, Y. Y. V. D., Wittekoek, M. E., Beisiegel, U., Kastelein, J. J. P., & Koschinsky, M. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.4.361 · Cited by 184
Lipoprotein(a) as a risk factor for coronary artery disease
Marcovina, S. M., & Koschinsky, M. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00954-0 · Cited by 178
Self-citationCys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly.
Brunner, C., Kraft, H. G., Utermann, G., & Müller, H. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11643 · Cited by 153
Plasma Concentration of Lipoprotein(a) and the Risk of Future Stroke
Ridker, P. M. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520400039041 · Cited by 141
Berg, K., Dahlén, G., Christophersen, B., Cook, T., Kjekshus, J., & Pedersen, T. (1997) · Clinical Genetics · doi:10.1111/j.1399-0004.1997.tb04342.x · Cited by 136
Marcovina, S. M., Hobbs, H. H., & Albers, J. J. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.3.436 · Cited by 130
Self-citationAustin, M. A., Rodriguez, B. L., McKnight, B., McNeely, M. J., Edwards, K. L., Curb, J. D., & Sharp, D. S. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00956-5 · Cited by 129
Rifai, N., Ma, J., Sacks, F. M., Ridker, P. M., Hernandez, W. J. L., Stampfer, M. J., & Marcovina, S. M. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.030031 · Cited by 125
Self-citationFirst WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B
Dati, F., Tate, J. R., Marcovina, S. M., & Steinmetz, A. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.114 · Cited by 124
Self-citationKronenberg, F., Trenkwalder, E., Dieplinger, H., & Utermann, G. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.12.1568 · Cited by 101
Lamon-Fava, S., Marcovina, S. M., Albers, J. J., Kennedy, H., DeLuca, C., White, C. C., Cupples, L. A., McNamara, J. R., Seman, L. J., Bongard, V., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012526 · Cited by 90
Self-citationAlbers, J. J., Kennedy, H., & Marcovina, S. M. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37647-1 · Cited by 80
Self-citationWhen should we measure lipoprotein (a)?
Kostner, K. M., Marz, W., & Kostner, G. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht053 · Cited by 77
Tate, J. R., Berg, K., Couderc, R., Dati, F., Kostner, G. M., Marcovina, S. M., Rifai, N., Sakurabayashi, I., & Steinmetz, A. (1999) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1999.140 · Cited by 75
Self-citationA structural assessment of the apo[a] protein of human lipoprotein[a]
Guevara, J., Knapp, R. D., Honda, S., Northup, S. R., & Morrisett, J. D. (1992) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340120212 · Cited by 68
Brown, W. V., Ballantyne, C. M., Jones, P. H., & Marcovina, S. M. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.07.002 · Cited by 59
Self-citationLipoprotein(a) mass: A massively misunderstood metric
McConnell, J. P., Guadagno, P. A., Dayspring, T. D., Hoefner, D. M., Thiselton, D. L., Warnick, G. R., & Harris, W. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.003 · Cited by 57
Lassman, M. E., McLaughlin, T. M., Zhou, H., Pan, Y., Marcovina, S. M., Laterza, O., & Roddy, T. P. (2014) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6883 · Cited by 50
Self-citationGaubatz, J. W., Hoogeveen, R. C., Hoffman, A. S., Ghazzaly, K. G., Pownall, H. J., Guevara, J., Koschinsky, M. L., & Morrisett, J. D. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31535-2 · Cited by 49
Scanu, A. M., & Edelstein, C. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34933-6 · Cited by 44
Fless, G. M., & Santiago, J. Y. (1997) · Biochemistry · doi:10.1021/bi961941k · Cited by 5
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Available methods are, to a varying degree, influenced by the Apo(a) isoform.(91) Furthermore, the concentration of Lp(a) is reported as either a molar concentration (nmol/L) or as a mass (mg/ dL) by the various assays, and conversion between molar and mass concentrations has been found to be both size- and concentrat…”
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“This topic was recently reviewed by Marcovina and Albers (40), which provided full details of assay methodologies and limitations.”
BackgroundInfluentialLipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citation
Metadata
- Authors
- Marcovina, S. M., & Albers, J. J.
- Affiliations
- University of Washington (US)
- Corresponding author
- Marcovina, Santica M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 57
- Issue
- 4
- Pages
- 526-537
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4808779
- OpenAlex
- W2313206757
- Cited by
- 338
- References
- 49
- Citations by year
- 2026: 44 · 2025: 36 · 2024: 37 · 2023: 45 · 2022: 31 · 2021: 29 · 2020: 35 · 2019: 28 · 2018: 16 · 2017: 26 · 2016: 11
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1631 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), apolipoprotein(a), apo(a) isoforms, immunoassay standardization, antibody specificity, size heterogeneity, assay validation, measurement harmonization, coronary artery disease risk, clinical interpretation
- MeSH terms
- Apolipoproteins A, Cardiovascular Diseases, Data Interpretation, Statistical, Humans, Immunoassay, Reference Standards, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.